Treatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
|
|
- Roberta Hunt
- 5 years ago
- Views:
Transcription
1 Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria
2 A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha 4. Temsirolimus 5. Pazopanib 6. Everolimus 7. Axitinib
3 Trials Conducted in First-Line Agent tested in 1 st -line ORR (%) vs comparator PFS (months) vs comparator OS (months) Sunitinib 1,2 47 vs vs vs 21.8 Bev + IFN 3 31 vs vs vs 21.3 Bev + IFN 4 26 vs vs vs 17.4 Sorafenib vs vs 5.6 na Pazopanib 6 32 vs 4 a 11.1 vs 2.8 a 22.9 b Temsirolimus 7c 8.6 vs vs vs 7.3 Pazopanib vs Sunitinib 8 31 vs vs vs Motzer et al. NEJM 2007; 356: ; 2. Motzer et al. J Clin Oncol 2009; 27: ; 3. Escudier et al. Lancet 2007; 370: ; 4. Rini et al. J Clin Oncol 2008; 26: ; 5. Escudier et al. J Clin Oncol 2009; 27: ; 6. Sternberg et al. J Clin Oncol 2010; 28: ; 7. Hudes et al. NEJM 2007; 356: ; 8. Motzer et al. ESMO 2012; Abstract LBA8_PR (Oral presentation) a first-line patients only; b total population; c temsirolimus monotherapy group; na: not applicable
4 Trials Conducted after Cytokine Failure Agent n ORR % PFS months HR Sorafenib vs Pazopanib vs Sunitinib Axitinib Escudier B et al., New Engl J Med 2007; Sternberg C et al., J Clin Oncol 2010; Motzer RJ et al., Lancet Motzer RJ et al., JAMA 2006; 4.Rini B et al., Lancet 2011
5 Trials Conducted after anti-vegf-failure n ORR% PFS OS Everolimus vs vs vs 14.4 vs Placebo 1 Axitinib versus Sorafenib 2 Temsirolimus vs Sorafenib vs vs vs and vs vs Statistically significant difference 1. Motzer RJ et al., Lancet 2008; 2. Rini B et al., Lancet 2011; 3.Hutson T et al., ESMO 2012
6 Treatment guidelines for clear cell mrcc: ESMO 2012 Setting Treatment group Standard recommendation Level of evidence Longterm survival First-line Favourable or intermediate risk Sunitinib Bevacizumab + IFN-α Pazopanib* I, A I, A II, B Poor risk Temsirolimus I, B Second-line Post-cytokines Axitinib Sorafenib Pazopanib * I, A I, A II, A Post-TKI Axitinib Everolimus I, B II, A Third-line Post two TKIs Everolimus II, A *Conditionally approved Escudier B et al. Ann Oncol 2012;23(suppl 7):vii65-vii71
7 Treatment guidelines for clear cell mrcc: ESMO 2012 Setting Treatment group Standard recommendation Level of evidence Longterm survival First-line Favourable or intermediate risk Sunitinib Bevacizumab + IFN-α Pazopanib* I, A I, A II, B Poor risk Temsirolimus I, B Second-line Post-cytokines Axitinib Sorafenib Pazopanib * I, A I, A II, A Post-TKI Axitinib Everolimus I, B II, A Third-line Post two TKIs Everolimus II, A *Conditionally approved Escudier B et al. Ann Oncol 2012;23(suppl 7):vii65-vii71
8 Relevance of Two versus One Treatment Options for Patients with Favourable- Intermediate Risk For the patients: the more options, the better For the treating physician: Awareness of potential differences between agents Responsibility to choose the individually best treatment The need to use it well in order to optimize the outcome because only one agent will be reimbursed
9 Relevance of Two versus One Treatment Options for Patients with Favourable- Intermediate Risk For the patients: the more options, the better For the treating physician: Awareness of potential differences between agents Responsibility to choose the individually best treatment The need to use it well in order to optimize the outcome because only one agent will be reimbursed
10 Sunitinib, Pazopanib What Do Randomized Trials Tell Us?
11 PISCES Study Pazopanib versus sunitinib patient preference study in treatment naïve advanced or metastatic renal cell carcinoma
12 Study Design of PICSES Randomisation n=169 No prior tx Measurable or non-measurable Disease Any histology ECOG 0 or 1 Pazopanib 800 mg once daily, 10 weeks Sunitinib 50 mg 4/2, 10 weeks Period 1 Sunitinib 50 mg 4/2, 10 weeks Pazopanib 800 mg once daily, 10 weeks 2-week washout Period 2 Double-blind Patient choice of treatment to progression Off study 1:1 randomisation Time (weeks) Both drugs were over-encapsulated Patients on sunitinib received placebo during 2-week off-period 1. ClinicalTrials.gov. NCT
13 Patients (%) PISCES Trial: Primary endpoint: Patient preference for study treatments (Primary analysis population) % CI (for difference): ; p< % (n=80) 22% (n=25) 8% (n=9) Preferred pazopanib Preferred sunitinib No preference 1. Escudier B, et al. ASCO 2012 oral presentation; abstract 4502.
14 Summary of all reasons given for patient preference 1 Better quality of life Less fatigue Less taste change Less mucositis/stomatitis Less nausea/vomiting Less hand-foot syndrome Pazopanib preferred (n=80) Sunitinib preferred (n=25) Better appetite Less stomach pain Less diarrhoea Other Less hair colour change Number of patients 1. Escudier B, et al. ASCO 2012 oral presentation; abstract 4502.
15 COMPARZ: Pazopanib vs. Sunitinib Treatment-naïve advanced or metastatic RCC patients Primary endpoint: PFS Secondary endpoint(s): OS, ORR, Safety, QOL R A N D O M I Z E Pazopanib 800 mg daily 1:1 Randomization N = 876 Sunitinib 50 mg 4 wks / 2 wks * Sunitinib PFS no more than 25% better than A/P PFS (e.g. 8.8 vs.11 months at median) / 80% Power to detect non-inferiority Motzer et al., ESMO 2012
16 COMPARZ: Non-Inferiority Trial Design that aimed to show that pazopanib is not worse than sunitinib by more than a pre-specified small amount (which is deemed clinically acceptable) the non-inferiority margin 1 How is the Non-inferiority margin defined? Protocol-defined criterion: hazard ratio upper bound of a twosided 95% CI of <1.25 European Medicines Agency (CHMP) -defined criterion: hazard ratio upper bound of a two-sided 95% CI of 1.22 for both, the ITT and PP-population 1.Piaggio G et al. JAMA 2012;308:
17 COMPARZ: Progression-free Survival (primary endpoint - independent review) N Median PFS (95% CI) Pazopanib mo (8.3, 10.9) Sunitinib mo (8.3, 11.1) HR (95% CI ) (0.898,1.220) ORR PAZ: 31% SUN 25% Pazopanib Sunitinib Motzer et al., ESMO 2012
18 Most Common Adverse Events Pazopanib (n = 554) % Sunitinib (n = 548) % Adverse Event a All Grs Gr 3/4 All Grs Gr 3/4 Any event b >99 59/15 >99 57/17 Diarrhea 63 9/0 57 7/<1 Fatigue 55 10/< /<1 Hypertension 46 15/< /<1 Nausea 45 2/0 46 2/0 Decreased appetite 37 1/0 37 3/0 ALT increased 31 10/2 18 2/<1 Hair color changes 30 0/0 10 <1/0 Hand-foot syndrome 29 6/ /<1 Taste Alteration 26 <1/0 36 0/0 Thrombocytopenia 10 2/< /4 a AE 30% in either arm b 2% of patients in pazopanib arm and 3% of patients in sunitinib arm had grade 5 adverse events.
19 Instrument Domain Description Treatment difference : mean change from baseline 2 P -value FACIT-F Fatigue/Total score 2.32 <0.001 FKSI-19 Cancer Treatment Satisfaction Questionnaire (CTSQ) Supplementary Quality of Life Questionnaire (SQLQ) Quality of Life Results (first 6 months 1 ) Kidney Symptom Index/Total score Physical Emotional Treatment Side Effects Functional Well Being Expectations of Therapy Feelings about Side Effects 8.50 <0.001 Satisfaction with Therapy 3.21 <0.001 Worst mouth/throat soreness < Worst foot soreness Worst hand soreness Limitations due to mouth/throat soreness 0.94 <0.001 Limitations due to foot soreness Pre-specified analysis. HRQoL changes in mean scores over time were analyzed with a repeated measures analysis of covariance (ANCOVA). 2 Yellow Font: favors pazopanib. Blue Font: favors sunitinib. P-value <0.05 is statistically significant
20 Have COMPARZ and PISCES Identified Pazopanib as the Better TKI? The most obvious conclusion: sunitinib has not been used well in these trials Results are by far below from our own experience
21 Outcome of Sunitinib-Patients: Single Center Experiences in Large Cancer Centers Center ORR % PFS months OS months Department of Urology Chungnam National University School of Medicine Daejeon Medical University Vienna Oncology Asan Medical Center Seoul 3 1.Hwang E et al., Korean J Urol 2010; 2.Schmidinger M et al., manuscript in preparation 3.Yoo C et al., Jpn J Clin Oncol 2010;
22 Reasons for Better Outcome in Real World: COMPARZ versus TKI-Experience in Real World PAZ COMPARZ SUN COMPARZ SUN VIENNA Dose reductions% Toxicity-related treatment discont ORR PFS OS Motzer RJ, et al. ESMO 2012, 2. Schmidinger M, et al. Manuscript submitted
23 Can The Way a Drug is Used and the Trial Design Impact the Primary Endpoint, PFS in a Clinical Study?
24 COMPARZ Challenges in Non-Inferiority Trials In non-inferiority trials, many problems can bias the ITT analysis towards showing apparent non-inferiority where it did not really exist When the results of the ITT and PP analyses are inconsistent the results should be interpreted based on the more conservative dataset (ie PP analysis for non-inferiority studies) 1 lar c 1..ICH E9 Guidelines. Note for guidance for statistical principles for clinical trials. September 1998 CPMP/ICH/363/96.
25 COMPARZ: Inconsistent Results in the Primary Endpoint 1,2 - HR: upper bound of 95% CI <1.25 or CHMP requested ( 1.22) ITT: Median PFS met non-inferiority criteria PP: Median PFS did not meet non-inferiority criteria PFS (IRC-Assessed, ITT Population) Pazopanib (N=557) SUTENT N=553) Median PFS, months (95% CI) 8.4 ( ) 9.5 ( ) HR (95% CI) ( ) PFS (IRC-Assessed, PP Population) Pazopanib (N=501) SUTENT (N=494) Median PFS, months (95% CI) 8.4 ( ) 10.2 ( ) HR (95% CI) ( ) PFS (Investigator-Assessed, ITT Population) Pazopanib (N=557) SUTENT (N=553) Median PFS, months (95% CI) 10.5 ( ) 10.2 ( ) HR (95% CI) ( ) 1. GSK. Clinical Study Register. Study Available at: (last accessed February 2013). 2. Data on file. Motzer RJ, et al. ESMO 2012, Vienna, Austria. Abstract LBA8_PR, oral presentation.
26 Summary PISCES and COMPARZ PISCES Patients prefer pazopanib to sunitinib when asked on day 28 of treatment Patient rate their QoL better with pazopanib than sunitinib COMPARZ Primary endpoint: Non-inferiority of pazopanib questionable: PP-PFS 8.4 vs 10.2 months QoL data questionable because assessed on day 28 of treatment Sunitinib has not been used well: 51% dose reductions, 7.6 months treatment duration Timepoint of response assessment unfavoured sunitinib Inclusion of 300 Asian patients unfavoured sunitinib However: fewer HFS, taste alterations, fatigue, thrombocytopenia In contrast: more ALT increase and diarrhoe with pazopanib
27 Implications for Clinical Practise
28 Relevance of Two versus One Treatment Options for Patients with Favourable- Intermediate For the patients: the more options, the better For the treating physician: Awareness of potential differences between agents Responsibility to choose the individually best treatment The need to use it well in order to optimize the outcome because only one agent will be reimbursed
29 Which Agent for Which Patient? If QoL rather than efficacy is your primary treatment goal: pazopanib is a good choice If efficacy=long term survival is your primary treatment goal: sunitinib might still be the better choice
30 Patient RK: an Ideal Pazopanib-Patient Male patient, age at diagnosis of RCC 66 Nephrectomy 1998 January 2011, at the age of 79, diagnosis of lung and bone metastases, low tumor bulk MSKCC intermediate risk (anemia) Co-morbidities: coronary artery disease, hypertension, ECOG 2 Individual treatment goal: maintaing QoL, should not have any limitations due to disease or treatment
31 Patient RK Begin Pazopanib 800 mg January 2011 Toxicities Hypertension 2 Fatigue 1 Diarrhoea 2 Nausea 1 Anorexia 1 Best response: SD PFS 23+ months Individual treatment goal achieved: no cancer-related symptoms due to successful treatment No major impairments in QoL
32 Which Agent for Which Patient? If QoL rather than efficacy is your primary treatment goal: pazopanib is a good choice If efficacy=long term survival is your primary treatment goal: sunitinib might still be the better choice Is a 2 months improvement in PFS relevant for longterm survival?
33 Why is First-Line TKI Outcome so Important? The longer progression-free survival in first-line, the longer overall survival in later lines 1 31 studies, patients: 10% relative risk reduction (RRR) for PFS/TTP was associated with a 6% RRR for OS A 1-month gain in median PFS/TTP was associated with a month gain in median OS (95% CI: 0.59,1.76; R(2)=0.28) 1.Delea TE, British Journal of Cancer 2012
34 Case Patient SN Male patient, 46 years of age at diagnosis of RCC August 2004: Diagnosis of a tumor on the right kidney and lung metastases MSKCC-risk: Hemoglobin 15.4 g/dl, LDH 154 U/L, cca 2+ : 1.2 mmol/l, PFS: ECOG 0, TDM <1year Intermediate Palliative nephrectomy and metastasectomy cc-rcc, pt3a, N0, M0
35 Case Patient SN February 2005: 5 months after metatsasectomy, diagnosis of new lung metastases Begin cytokine treatment (IL-2, IFN-alpha sc) Best response PR PD November 2005, PFS 9 months Patient is informed about arrival of new drug (sunitinib) in 3 months, willing to wait
36 Case Patient SN November 2005 to February 2006: No treatment, further progression February 2006: Begin sunitinib (50 mg/4/2) Toxicities: Fatigue Grade 2, resolved with physical activity, Diarrhoea Grade 2 February 2007: CR: sunitinib continued at 37.5 mg January 2009: PD: one new lung lesion, PFS: 35 months
37 Case Patient SN February 2009: Therapeutic decision Stereotactic radiosurgery and sunitinib continuation at 37.5 mg Staging January 2010: CR sunitinib continuation (37.5 mg) January 2012: PD, new pancreatic lesion Therapeutic decision_ Increase of sunitinib to 50 mg Referred to surgeon, plan to perform metastasectomy Patient requested more time to decide on surgery April 2012: PR October 2012: CR
38 Treatment Summary and Messages PFS 1st-line cytokine treatment: 9 months After progression on cytokines, initiation of sunitinib: 1st PFS: 35 mo At PD, SU 37.5 continued+stereotactic radiosurgery: 2nd PFS: 24 mo At PD sunitinib increased to 50 mg: 3rd PFS: 12+ mo So far, sunitinib enabled a survival of 7+ years since progression on cytokines Appropriate side effect management allowed long term treatment QoL in a sunitinib-long term survivor: Has learned how to deal with side effects Has lost his fear to die from the disease Is leading an almost normal life
39 Relevance of Two versus One Treatment Options for Patients with Favourable- Intermediate For the patients: the more options, the better For the treating physician: Awareness of potential differences between agents Responsibility to choose the individually best treatment The need to use it well in order to optimize the outcome because only one agent will be reimbursed
40 If Only One Agent is Reimbursed: Use it well Inform your patient appropriately about potential side effects Provide prophylactic and supportive measures Whenever a side effect is difficult to manage, e.g. taste changes, consider changing the schedule (4/2 to 2/1) rather than offering dose reductions Inform your patient about the importance of dosing and the dose response relationship Critically question disease progression: frequently, it s a matter of inappropriate dosing rather than resistance
41 Case Patient WS: Progression as a Matter of Inappropriate Dosing/Compliance Staging Results and Date PR Nov 2009 Jan 2010 May 2010 Jan 2011 Apr 2011 CR Aug 2010 Jul 2011 Oct 2011 Jan 2012 Apr 2012 PD Nov 2010 Jul 2012 Apparent resistance15 mo True resistance 33 months Sunitinib 50 mg Sunitinib 37.5 mg Dose of sunitinib before staging CT Sunitinib 25 mg
42 Case Patient FH: Progression as a Matter of Inappropriate Dosing PR CR PD SEPT 2010 DEC 2010 Staging Results and Date APR 2011 AUG 2011 DEC 2011 MAR 2012 JUL 2012 DEC 2012 Next Staging March 2012 Apparent resistance 7 mo Ongoing CR after 31 months Sunitinib 50 mg Sunitinib 37.5 mg Dose of sunitinib before staging CT Sunitinib 25 mg
43 Conclusions The therapeutic landscape of mrcc management has dramatically improved over the last 7 years The more agents we can offer, the better it is for the patient We need to choose the best agent for the individual patient We need to be aware of differences between agents and define the best individual treatment goal We need to offer appropriate therapy management We need to be aware that QoL is individually defined
44 What is QoL for the Individual Patient? And in the end it's not the years in your life that count; it's the life in your years* Statement of patient EA, 49 years, physician mrcc: that s wrong it s my own task to bring life to my years, from my physician, I expect to bring years to my life Bringing years to the life of a patient=choosing a treatment based on efficacy criteria and using it well For many of our patients, efficacy of an agent largely contributes to QoL! *Abraham Lincoln ( )
Linee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationDose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring
Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring Alison Zhang 1, Peter Fox 1, Sally Coulter 4, Val Gebski 5, Bavanthi Balakrishnar 1, Christopher Liddle
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationOpinion 26 June 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 26 June 2013 VOTRIENT 200 mg, film-coated tablets B/30 (CIP: 491 313 4) VOTRIENT 400 mg, film-coated tablets B/30
More informationRenal Cell Carcinoma
Renal Cell Carcinoma Sequencing in renal cancer: two options for the same problem (TKImTOR) Viktor Grünwald Clinic for Hematology, Hemostasis, Oncology and Stemcelltransplantation Prof. Viktor Grünwald
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationA Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Kim et al. BMC Urology (2016) 16:46 DOI 10.1186/s12894-016-0163-5 RESEARCH ARTICLE Open Access A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationCase(s): How to Deal with Mixed Response Giuseppe Procopio
Case(s): How to Deal with Mixed Response Giuseppe Procopio Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Disclosures Advisory: Astellas, Bayer, GSK Consultant: Pfizer, Novartis Background Mixed
More informationTreatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE
Tivozanib Hydrochloride in Advanced Renal Cell Carcinoma ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE AVEO PHARMACEUTICALS, INC. 75 Sidney Street Cambridge, MA 02139 Tel: (617) 299-5000
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
into consideration the concerns of the patient. Upon reconsideration of the perc Initial Recommendation,the Committee discussed feedback from the patient advocacy group reporting concerns that the definition
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationWhy was HOPE 205 a Positive After Years of Negative Studies?
Why was HOPE 205 a Positive After Years of Negative Studies? Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Why do we pursue combinations?
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationHow does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy
How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Targeting VHL/HIF in Clear Cell RCC VHL Bevacizumab (Antibody)
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationRenal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland
Renal Cell Cancer Clinical case study 1 & 2 Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland 1 Case study 1 - RCC and Lung Metastases Case study 1: Patient History Male, 63 years old Mild
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationCANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /
CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
More informationTherapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 2275-2280, 2015 Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis QINXIANG TAN 1*,
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationCLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12
Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationCheckMate 025, as patients may derive a benefit, based on the opinion of the CGP and the mechanism of action of nivolumab.
CheckMate 025, as patients may derive a benefit, based on the opinion of the CGP and the mechanism of action of nivolumab. perc noted that patients with brain metastases were excluded from the CheckMate
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationAxitinib in renal cell carcinoma: now what do we do?
Renal Cell Carcinoma Axitinib in renal cell carcinoma: now what do we do? Ian D. Davis Monash University Eastern Health Clinical School, Level 2, Box Hill, Victoria 3128, Australia Correspondence to: Ian
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationThe Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations
Evidence-Based Series #3-8-4: Section 1 The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations S. Hotte, T. Waldron,
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationAtezolizumab Adjuvant Study: Medical Oncologist Perspective. Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center
Atezolizumab Adjuvant Study: Medical Oncologist Perspective Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center Trial overview Key issues Outline Challenges with neoadjuvant therapy Placebo control
More informationWhat can we expect from running phase III trials: will all of them alter the current treatment algorithm?
What can we expect from running phase III trials: will all of them alter the current treatment algorithm? 8 th European International Kidney Cancer Symposium Budapest, May 2013 Martin Gore PhD FRCP Royal
More informationSBRT for lung metastases: Case report
SBRT for lung metastases: Case report Guillermo de Velasco MD, PhD University Hospital 12 de Octubre @H12O_GUCancer @g_develasco Case report 71 years old man Smoker DM 2005 Right radical nephrectomy Histology:
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationPrognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More information17/01/2017. Use of kinase inhibitors in oncology practice. Multikinase inhibitors. Sunitinib (Sutent )targets. Many more sunitinib kinase targets (42)
Multikinase inhibitors Use of kinase inhibitors in oncology practice Prof Jacques De Grève, UZ Brussel Inhibit multiple intracellular and cell surface kinases Tyrosine or serine-threonine kinases Multitargeting
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationClick to edit Master /tle style. Cardiovascular Toxicity in Renal Cell Carcinoma Pa/ents
Click to edit Master /tle style Cardiovascular Toxicity in Renal Cell Carcinoma Pa/ents Bernhard J. Eigl MD FRCPC Medical Oncologist, BC Cancer Agency Clinical Associate Professor, University of Bri/sh
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationWhen to Treat Beyond Progression with Systemic Therapies? Manuela Schmidinger Medical University of Vienna, Austria
When to Treat Beyond Progression with Systemic Therapies? Manuela Schmidinger Medical University of Vienna, Austria Is Treatment Beyond Progression a Valid Strategy? 1) NO YES? Is Treatment Beyond Progression
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationTechnology appraisal guidance Published: 25 February 2015 nice.org.uk/guidance/ta333
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment Technology appraisal guidance Published: 25 February 2015 nice.org.uk/guidance/ta333 NICE 2018. All rights
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationComplex case Presentations
Complex case Presentations Case Presentations April 2016 Lisa M Pickering Case presentations: chromophobe renal carcinoma 60 year old man. ECOG PS 0 No significant comorbodities August 2009: L radical
More informationA Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of With or Without Bevacizumab vs in Untreated Metastatic Renal Cell Carcinoma Patients David McDermott, 1 Michael Atkins, 2 Robert Motzer, 3 Brian Rini, 4 Bernard Escudier, 5 Lawrence
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationScottish Medicines Consortium
Scottish Medicines Consortium sorafenib 200mg tablets (Nexavar ) (No. 321/06) Bayer Plc 6 October 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Lenvatinib (Lenvima) for Renal Cell Carcinoma
pan-canadian Oncology Drug Review Final Clinical Guidance Report Lenvatinib (Lenvima) for Renal Cell Carcinoma January 4, 2019 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationcombination with everolimus with other relevant treatment options, perc considered the results of a submitted indirect treatment comparison (ITC) that included comparisons of lenvatinib in combination
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationEfficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.5.1971 Efficacy and Toxicity of Sunitinib in Egyptian Patients with Metastatic Renal Cell Carcinoma RESEARCH ARTICLE Efficacy and Toxicity of Sunitinib in Metastatic
More informationA Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients Viktor Grünwald, 1 David McDermott, 2 Michael Atkins, 3 Robert Motzer, 4
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More information